DNAJC5 and malaria: This signature generates hypotheses about the RTS,S clinical mode of action and complements anti-CSP antibody levels for predicting which vaccine recipients will be protected—thereby providing a convenient readout for currently uncharacterized immune mechanisms that, together with binding antibodies, protect against malaria challenge.